By Robin Carhart-Harris — 2020
At Imperial College we’ve been comparing psilocybin to conventional antidepressants—and the results are likely to be game-changing.
Read on www.theguardian.com
CLEAR ALL
The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found that the former improved symptoms of depression just as well on an established metric—and had fewer side effects.
1
A new generation of research into psilocybin could change how we treat numerous mental health conditions.
Often, disabled people have their disability treated, but they don’t have their emotional or spiritual needs addressed.
The mind-altering drug has been shown to help people suffering from anxiety and depression. But how it helps, who it will serve, and who will profit are open questions.
My first encounter with ketamine did not go well.
2
A single dose of psilocybin, a compound found in “magic mushrooms,” provides long-term relief of anxiety and depression in cancer patients, a new study finds.
3
The new research looked at cancer patients who took part in a study nearly five years ago.
Michael Phelps, the most decorated athlete in Olympic history with 28 medals, has acknowledged that after the 2012 games, his longtime depression was so overwhelming he thought about killing himself.
Demand from patients seeking help for their mental illnesses has led to underground use in a way that parallels black markets in the AIDS pandemic. This underground use has been most perilous for people of color, who face greater stigma and legal risks due to the War on Drugs.
Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.